Mental Health Clinics in Riverdale, NJ Accepting Medicare
2 Mental Health Clinics found. Showing 1 - 2
 Grace Counseling Ministries, Inc. Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 73 Newark Pompton Tpke, Riverdale, NJ 07457 Phone: 973-835-2071 Fax: 973-835-2083 |
Elyse Guli Licensed Clinical Social Worker Llc Social Worker - Clinical Medicare: Not Enrolled in Medicare Practice Location: 106 Route 23 N, #1003, Riverdale, NJ 07457 Phone: 201-887-0139 |
News Archive
Trial results show primary care doctors are capable of helping obese patients to lose weight
Despite a general belief among physicians that extreme obesity is too difficult to treat, except with bariatric surgery, researchers at the Pennington Biomedical Research Center have learned a substantial proportion of individuals with extreme obesity can lose 10-percent or more of their body weight through medical treatment that does not include surgery.
New therapeutic strategy is emerging for type 2 diabetes
Diabetes is a disease in which blood sugar levels are high over a prolonged period (hyperglycemia). In the case of type 2 diabetes, this phenomenon which is caused by a disruption of the glucose metabolism develops progressively and insidiously.
Physicians warn parents on dangers of prescription drug abuse among children
With reports of increased prescription drug overdoses in emergency departments, the nation's emergency physicians are issuing a strong warning to parents about the dangers of abusing prescription drugs, which are now the second most abused drugs, after marijuana. Hospital visits caused by accidental and unintentional prescription drug overdoses went up 37 percent between 1999 and 2006, according to new data released by the American Journal of Preventive Medicine.
Study demonstrates direct effects of fragmented sleep on tumor growth
Poor-quality sleep marked by frequent awakenings can speed cancer growth, increase tumor aggressiveness and dampen the immune system's ability to control or eradicate early cancers, according to a new study published online January 21, 2014, in the journal Cancer Research.
Transcept initiates enrollment in TO-2061 Phase 2 study for treatment resistant obsessive compulsive disorder
Transcept Pharmaceuticals, Inc. today announced the first patient has been enrolled in a Phase 2 clinical study to evaluate TO-2061 as an adjunctive treatment for obsessive compulsive disorder (OCD) in patients who have responded inadequately to currently approved treatments. OCD affects 1 to 2 percent of the United States adult population and can significantly impair the lives of patients and their families.
› Verified 7 days ago